The current treatment regimen for MDR-TB has poor outcomes and costs of treating MDR-TB are
greater than treating drug susceptible TB, both in terms of health service and
patient-incurred costs. Urgent action is needed to Identify short, effective and tolerable
treatments for people with MDR-TB. The PRACTECAL economic evaluation sub-study (PRACTECAL-EE)
will take place alongside the TB PRACTECAL trial, aiming to assess the costs to patients and
providers of such regimens and to estimate the cost-effectiveness and poverty impact of an
introduction of new MDR-TB regimens in the three countries participating in the main study.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Medecins Sans Frontieres, Netherlands
Collaborators:
Clinical HIV Reserach Unit, Wits Health Consortium Liverpool School of Tropical Medicine London School of Hygiene and Tropical Medicine LSHTM Clinical Research Department Ministry of Health, Belarus Ministry of Health, Republic of Uzbekistan Ministry of Public Health, Republic of Belarus TB & HIV Investigative Network (THINK) THINK TB & HIV Investigative Network University of Liverpool Wits Health Consortium (Pty) Ltd
Treatments:
Bedaquiline Clofazimine Diarylquinolines Linezolid Moxifloxacin Norgestimate, ethinyl estradiol drug combination